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The overlap of genetic 
susceptibility to schizophrenia 
and cardiometabolic disease can 
be used to identify metabolically 
different groups of individuals
Rona J. Strawbridge1,2,3*, Keira J. A. Johnston1,4,5, Mark E. S. Bailey5, 
Damiano Baldassarre6,7, Breda Cullen1, Per Eriksson3, Ulf deFaire8, Amy Ferguson1,9, 
Bruna Gigante3, Philippe Giral10, Nicholas Graham1, Anders Hamsten3, Steve E. Humphries11, 
Sudhir Kurl12, Donald M. Lyall1, Laura M. Lyall1, Jill P. Pell1, Matteo Pirro13, Kai Savonen14,15, 
Andries J. Smit16, Elena Tremoli7, Tomi‑Pekka Tomainen17, Fabrizio Veglia7, Joey Ward1, 
Bengt Sennblad18 & Daniel J. Smith1
Understanding why individuals with severe mental illness (Schizophrenia, Bipolar Disorder and Major 
Depressive Disorder) have increased risk of cardiometabolic disease (including obesity, type 2 diabetes 
and cardiovascular disease), and identifying those at highest risk of cardiometabolic disease are 
important priority areas for researchers. For individuals with European ancestry we explored whether 
genetic variation could identify sub‑groups with different metabolic profiles. Loci associated with 
schizophrenia, bipolar disorder and major depressive disorder from previous genome‑wide association 
studies and loci that were also implicated in cardiometabolic processes and diseases were selected. 
In the IMPROVE study (a high cardiovascular risk sample) and UK Biobank (general population 
sample) multidimensional scaling was applied to genetic variants implicated in both psychiatric and 
cardiometabolic disorders. Visual inspection of the resulting plots used to identify distinct clusters. 
Differences between these clusters were assessed using chi‑squared and Kruskall‑Wallis tests. In 
IMPROVE, genetic loci associated with both schizophrenia and cardiometabolic disease (but not 
bipolar disorder or major depressive disorder) identified three groups of individuals with distinct 
metabolic profiles. This grouping was replicated within UK Biobank, with somewhat less distinction 
between metabolic profiles. This work focused on individuals of European ancestry and is unlikely 
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to apply to more genetically diverse populations. Overall, this study provides proof of concept that 
common biology underlying mental and physical illness may help to stratify subsets of individuals with 
different cardiometabolic profiles.
Individuals with serious mental illness (such as schizophrenia (SCZ), major depressive disorder (MDD) and 
bipolar disorder (BD)) have a reduced life expectancy (10–15 years for BD, 15–20 years for  SCZ1). This is likely 
due to the well-established increased prevalence of cardiovascular and metabolic disorders compared to the 
general population. For example, obesity is up to 3.5-fold higher in those with  SCZ2, type 2 diabetes is ~ twofold 
higher in those with MDD, BD or  SCZ2, and cerebrovascular disease is increased by up to 3.3-fold in those with 
 BD2. Understanding this increased risk and identifying individuals at highest risk of metabolic and cardiovascular 
disease are important priority areas for researchers and healthcare providers.
Historically, the increased risk and prevalence of cardiometabolic disease (CMD) has been attributed to social 
determinants and lifestyle factors (including poor diet, sedentary behaviour, alcohol and substance use) that 
co-exist with serious mental illness and effects of psychotropic  medication2, however there is growing evidence 
that there might be common biological mechanisms underlying both mental and psychiatric illness. As genetic 
data is stable over an individual’s lifetime, and not influenced by disease course, genetic approaches are ideal for 
investigation of common biology in comorbid conditions. The identification of genetic variants robustly associ-
ated with a wide range of psychiatric and cardiometabolic phenotypes by international genetics consortia has 
enabled the exploration of relationships between psychiatric and cardiometabolic conditions.
Genome-wide genetic correlations between psychiatric and cardiometabolic traits provide evidence for 
underlying common biology. Correlations have been described between depression and obesity (rg = 0.12) or 
cardiovascular disease (rg = 0.42)3. Evidence of causal relationships between psychiatric and cardiometabolic 
traits have also been  described1,4,5. However, the mechanisms involved have yet to be uncovered and therefore 
this knowledge has had no clinical impact.
Here we tested whether a novel approach using multi-dimensional scaling (MDS) of genetic variation asso-
ciated with psychiatric and cardiometabolic disorders could aid stratification of individuals into groups with 
differing cardiometabolic risk profiles.
Results
The IMPROVE and UK Biobank studies. The demographic characteristics of the IMPROVE, UK 
Biobank subsets 1 (UKB1) and 2 (UKB2) are provided in Table 1. At baseline, individuals in IMPROVE (a Euro-
pean high cardiovascular-risk cohort) were older, more overweight and more likely to have T2D, hypertension 
or medication for hypertension or lipid-lowering medication than the UKB subsets (self-reported white British 
general population cohort). UKB1 and UKB2 were very similar, with lower frequency of hypertension at follow-
up in UKB1 (51.5%) compared to UKB2 (62.0%) but slightly larger carotid Intima-media thickness (cIMT, 
indicative of vessel wall remodelling) measures in UKB2 to UKB1. Despite different proportions of UKB1 and 
UKB2 completing the mental health questionnaire, the frequencies of BD, MDD and GAD were similar.
Figure 1 provides a schematic overview of the analysis procedure.
SCZ‑CM loci can identify metabolically distinct groups of individuals in IMPROVE. When using 
IMPROVE and single nucleotide polymorphisms (SNPs) with a minor allele frequency (MAF) > 1%, implicated 
in both SCZ and CMD (SCZ-CMD), plotting the first two multi-dimensional scaling components (C1 and C2) 
demonstrated 3 groups of individuals (by visual inspection) (Fig.  2a). Separation was predominantly due to 
C1, and whilst C1 is nominally significantly correlated with latitude (rho = − 0.036, p = 0.0339), the clustering is 
not being driven by latitude (Supplementary Fig. 1). SNPs with MAF as low as 1% might differ across popula-
tions (even within the same ancestry grouping), therefore robustness to MAF threshold also assessed. When 
using MAF > 5% showed additional groups (Fig. 2b), whereas MAF > 10% showed similar groups to MAF > 1% 
(Fig. 2c). Assignment to groups was consistent using MAF > 1% and MAF > 10% (Supplementary Table 1). The 
three groups appear to have modest differences in cardiometabolic profiles (Table 2): Group 3 had a significantly 
lower frequency of hypertension (group 3: 74% vs groups 1 or 2: 80% or 81% respectively, P = 0.004) and lower 
fastest progression of cIMT (group 3: 0.156 mm vs groups 1 or 2: 0.176 mm or 0.166 mm, P = 0.002). This is sur-
prising given the (non-significant) higher rates of smoking in this group. Group 2 had (non-significantly) lower 
rates of T2D than the other groups (group 2: 25% vs groups 1 or 3: 28%). Similar groups were observed using 
T-distributed Stochastic Neighbour Embedding (tSNE) or principal component analyses (PCA, Supplementary 
Methods), with the majority of individuals being consistently grouped together (Supplementary Figs. 2 and 3, 
respectively).
This result appears specific to SCZ-CMD SNP subset; no separation into groups was observed when using 
MDD-CMD SNPs, irrespective of the MAF filter used (Fig. 2d–f). For BD-CMD SNPs (Fig. 2g–i), grouping is 
apparent at MAF > 1%, but not when MAF > 5% or 10% were considered.
Validation of method and sensitivity testing of clustering in UKB1. In order to assess whether 
MDS analysis of SCZ-CMD SNPs could reproducibly identify three groups of individuals, validation of the 
method was attempted in UKB1. Firstly, to directly replicate the analysis conducted in IMPROVE (Fig. 3a,b), 
the post-filtering SNPs from IMPROVE were used (Fig. 3c); however the grouping is not convincing as there is 
little separation between the groups. Secondly, to assess robustness of the method to differences in MAF and LD 
structure between populations, the SCZ-CMD SNPs were filtered for MAF and LD in UKB1. As noted in Fig. 1, 
the majority of SNPs included in the two approaches were the same. Unsurprisingly, the SNPs that differed were 
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mainly those with MAF < 10%. Using SCZ-CMD and conducting MAF and LD filtering in UKB1, nine groups 
are evident when using SNPs with MAF > 1% (Fig. 3d), whereas three groups are observed when using SNPs 
with MAF > 10% (Fig. 3e). When comparing the metabolic profiles of the 3 groups, no significant differences 
Table 1.  Demographic characteristics of IMPROVE and UKB participants. Where: *, adjusted to provide 
estimates of treatment-naïve levels, as per Ehret etl al; na, not available.
IMPROVE UKB1 UKB2
Nmax 3300 2202 20,182
Male (%) 1695 (51.4) 1042 (47.3) 9759 (48.4)
Baseline
Age (years) 64.2 (5.4) 55.7 (7.6) 55.2 (7.5)
Weight (kg) 76.7 (15.1) 76.1 (14.5) 76.9 (14.8)
Waist (cm) 94 (13) 88 (12) 88 (13)
Hip (cm) 102 (10) 102 (8) 102 (8)
WHR 0.92 (0.09) 0.86 (0.09) 0.86 (0.09)
BMI (kg/m2) 27.3 (4.2) 26.4 (3.9) 26.6 (4.2)
SBP (mmHg) 142 (18) 136 (18) 136 (18)
DBP (mmHg) 82 (10) 82 (10) 82 (10)
SBP* (mmHg) 151 (21) 138 (19) 138 (19)
DBP* (mmHg) 88 (11) 83 (11) 83 (11)
T2D 880 (26.7) 46 (2.1) 45 (2.2)
HTN 2634 (79.8) 974 (45.0) 8765 (45.2)
HTN medication 1904 (57.7) 332 (15.2) 2820 (14.0)
Lipid-lowering medication 1623 (49.2) 172 (18.4) 1677 (18.9)
ISH 0 (0) 21 (1.0) 259 (1.3)
IMTmean (mm) 0.891 (0.199) na na
IMTmax (mm) 2.037 (0.813) na na
Current smoking 498 (15.1) 139 (6.3) 1234 (6.1)
Former smoking 1216 (36.9) 746 (33.9) 6656 (33.0)
Follow-up
Age 66.7 (5.4) 61.8 (7.5) 63.2 (7.5)
Weight na 75.6 (14.6) 76.3 (15.0)
Waist na 86 (12) 88 (12)
Hip na 100 (8) 101 (9)
WHR na 0.86 (0.08) 0.87 (0.09)
BMI na 26.4 (4.0) 26.5 (4.4)
SBP na 138 (20) 137 (18)
DBP na 83 (11) 79 (10)
SBP* na 140 (20) 141 (20)
DBP* na 81 (11) 81 (11)
T2D na 79 (3.6) 867 (4.3)
HTN na 1121 (51.5) 12,414 (62.0)
HTN medication na 466 (21.2) 4568 (22.7)
Lipid-lowering medication na 408 (22.3) 4557 (26.4)
ISH 119 (3.6) 43 (2.0) 333 (1.7)
IMTmean (mm) na 0.672 (0.119) 0.682 (0.125)
IMTmax (mm) na 0.888 (0.182) 0.914 (0.297)
Progression of IMTmean 0.0186 (0.032) na na
Progression of IMTmax 0.0439 (0.163) na na
Current smoking na 99 (4.6) 708 (3.5)
Former smoker na 742 (34.1) 6800 (33.9)
MHQ
Nmax (% of group) na 1528 (69.4) 10,079 (49.9)
BD na 28 (1.8) 196 (1.4)
MDD na 410 (29.9) 3512 (28.6)
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were seen (Fig. 4a and Table 3). This is unsurprising, given that it is a smaller cohort with a lower cardiovascular 
burden.
Validation of metabolic differences between clusters in UKB2. In an attempt to replicate the clus-
tering and validate the metabolic differences between groups, the larger UKB2 subset was analysed. As filter-
ing with MAF > 10% and 1% gave similar clusters, filtering with MAF > 10% was applied as it is more likely to 
generalise to other populations. Again, three major groups were identified (Fig. 4b), similar to those identified 
in IMPROVE and UKB1. Additional clusters between the major three groups were apparent, but they account 
for ~ 7% of the studied population, and were omitted from the groups.
Consistent with the IMPROVE study, clinically modest (and statistically significant) differences were observed 
in baseline SBP, SDP adjusted for blood-pressure medication, and frequency of hypertension and T2D (Table3). 
These effects were not observed at follow-up, potentially due to lifestyle or medications changes in response to 
baseline observations. It was also noted that the frequency of MDD but not BD differed between the groups. The 
number of SCZ in UKB2 is too low to provide meaningful statistics.
Impact of MDD/BD on clusters. As phenotypes and genetic loci for SCZ overlap with those for MDD and 
BD, it is perhaps unsurprising to see that the clusters include different proportions of individuals with MDD. To 
investigate whether these individuals were driving the clustering, the process was repeated in those without BD/
MDD separately from those with these diagnoses (using SNPs with MAF > 10%). In those without mental illness, 
similar to the overall UKB2, there were there main groups, intermediate clusters accounting for 7.4% of the sam-
ple (Fig. 5a). In those with mental illness the three clusters were observed, with better between-group separation 
and only 1.3% of the sample being ungrouped (Fig. 5b). Small but significant differences between groups were 
observed for blood pressure measures and rates of hypertension, in both those with and without mental illness 
(Supplementary Table 2). These results suggest that this method is applicable to the general population, as well 
as those with increased genetic burden for mental illness.
All genetic loci associated with SCZ do not identify clusters in UKB. To determine whether it is 
common biology (ie. Overlap in loci for SCZ and CMD) per se, rather than SCZ in general that drives the clus-
Figure 1.  Schematic of the analysis procedure used to identify clusters.
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tering, the same procedure was followed using all SNPs in loci associated with SCZ in UKB2, with the same MAF 
and LD filtering being applied prior to MDS analysis. As shown in Supplementary Fig. 4, SNPs in loci associated 
with SCZ do not separate individuals into groups. A further “negative control” experiment was conducted in 
UKB2. When repeating the analysis using the genetic loci (Supplementary Table 4) associated with eye  colour6,7, 
there was no evidence of subgroups (Supplementary Fig. 5). These results confirm that it is the overlap of SCZ 
and CMD loci (rather than a methodological artefact), and therefore probably common biological mechanisms, 
which are driving the clustering.
Discussion
This study provides proof of principle that, using the genetic overlap between SCZ and cardiometabolic disor-
ders, subsets of European ancestry individuals with different metabolic profiles can be identified. These findings 
support the existence of mechanisms common to SCZ and blood pressure regulation.
The discovery cohort IMPROVE deliberately recruited to identify genes and biomarkers associated with the 
risk of cardiovascular diseases, at a time when psychiatric disorders were typically excluded from non-psychiatric 
studies, therefore only a portion of the spectrum of psychiatric genetic burden is represented. In contrast, 
UKB1 and UKB2 are general population cohorts and therefore have a wider spectrum of both psychiatric and 
cardiometabolic disorder genetic burden, although it is recognised that the recruitment skews this distribution 
towards to the healthier segment of the  population8. It is therefore both striking that the grouping was present in 
IMPROVE, and unsurprising that the blood pressure and hypertension differences between groups were more 
modest in UKB2 than those in IMPROVE.
It is worth noting that similar groups were observed in the IMPROVE cohort, using three different methods 
and (where applicable) exploring a variety of parameter settings. This suggests that the grouping is robust. The 
metabolic profiles of the groups did not completely agree between the 3 cohorts, however the repeated observa-
tion of between-group differences in T2D and blood pressure/hypertension deserves further attention. If the 
method can be refined to better identify whether an individual is at increased risk of either hypertension or T2D 
would be of immense value. Even if the method is only robust in high CMD-risk populations (such as those with 
family history, multiple risk factors or psychiatric diagnoses), it could be of clinical importance.
Figure 2.  Results of MDS analysis in IMPROVE, using the loci in common between CMD and SCZ with 
(a) MAF > 1%, (b) MAF > 5% or (c) MAF > 10%; CMD and MDD with (d) MAF > 1%, (e) MAF > 5% or (f) 
MAF > 10%; CMD and BD with (g) MAF > 1%, (h) MAF > 5% or (i) MAF > 10%. Each data point is an individual 
therefore the individuals who are closer together are more genetically similar.
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It is interesting that the analyses using BD and MDD genetic loci did not enable clustering of individuals in the 
same way as was observed for SCZ, particularly given that BD and SCZ demonstrate an overlap in genetic loci. 
There are several possible explanations for this, most notably the ability to identify genetic loci for each mental 
illness: SCZ is clinically a more severe phenotype with diagnostic criteria that are relatively specific (for exam-
ple psychotic episodes). In comparison, MDD spans a wide spectrum severity, with phenotypic heterogeneity 
potentially diluting or obscuring some true genetic effects. Whilst BD can be considered an intermediate (some 
symptoms more severe than MDD, most are less severe than for SCZ) diagnostic criteria for MDD and BD over-
lap to a large degree as both involve episodes of depression, meaning that there is potential for misdiagnosis and 
therefore dilution of genetic effects for either trait. Another explanation is that the mechanisms leading to CMD 
in SCZ differ from those in MDD or BD, with processes that are represented on the CardioMetabo and Immuno 
chips failing to capture some pathological mechanisms. With this in mind, the finding of different frequencies 
of MDD in the groups was not anticipated, as the MDD genetics did not achieve any form of grouping, and the 
overlap of MDD and SCZ genetics is modest. However, MDD is highly heterogeneous, therefore it would be of 
interest to further explore whether there are any differences between the MDD cases in each group, specifically 
whether any of the groups corresponds to the recently proposed atypical depression  subtype9,10.
Genetic correlation analyses have begun to explore the common biology and causal relationships between 
psychiatric and cardiometabolic  diseases1,3,10, however these methods assume that the entire genome influences 
both sets of traits. The small to moderate correlations could suggest that it is only a portion of the genome that has 
common effects. In contrast, the current study focuses on only the parts of the genome that have been implicated 
Table 2.  Demographic characteristics of the IMPROVE participants, by cluster (MAF > 10%). Highlighted 
in bold are the significant (p < 0.05) differences between groups. Where: *, adjusted to provide estimates of 
treatment-naïve levels as per Ehret et al.; Statistical analyses compared levels or frequncies across groups 1, 2 
and 3. Ungrouped (.) were omitted from the analyses). **P for Pearsons chi square for categorical variables and 
Kruskal–Wallis for continuous variables; na, not available.
1 2 3 P**
N 1222 (36.2) 1629 (48.2) 526 (15.6)
Men (%) 581 (47.6) 842 (51.7) 268 (51.0) 0.954
Age (years) 64.2 (5.4) 64.2 (5.4) 64.4 (5.4) 0.558
BMI (kg/m2) 27.4 (4.3) 27.2 (4.2) 27.0 (4.2) 0.259
Waist (cm) 94.5 (12.8) 93.8 (12.4) 93.9 (12.6) 0.298
Waist_hip 0.92 (0.09) 0.92 (0.09) 0.94 (12.6) 0.859
SBP (mmHg) 142 (18) 142 (19) 140 (18) 0.070
DBP (mmHg) 82 (10) 82 (10) 82 (10) 0.599
HTN 982 (80.4) 1321 (81.1) 389 (74.0) 0.004
HTN medication 694 (56.8) 805 (58.1) 291 (55.3) 0.421
SBP* (mmHg)* 151 (20) 151 (21) 148 (21) 0.080
DBP* (mmHg)* 88 (11) 88 (11) 87 (12) 0.368
NSAIDs 253 (20.7) 260 (18.8) 102 (19.4) 0.622
Current smoking 172 (14.1) 246 (15.1) 87 (16.5) 0.614
Pack years 10.7 (17.2) 10.7 (15.9) 12.3 (19.7) 0.191
T2D 342 (28.0) 414 (25.4) 145 (27.6) 0.252
Lipid-lowering medication 585 (47.9) 828 (50.9) 256 (48.8) 0.159
Framingham risk score 0.27 (0.16) 0.27 (0.16) 0.27 (0.16) 0.743
Cardiac event 74 (6.1) 94 (5.8) 22 (4.2) 0.208
Baseline
CC-IMTmean 0.740 (0.130) 0.745 (0.147) 0.749 (0.155) 0.962
IMTmean 0.895 (0.198) 0.888 (0.199) 0.888 (0.205) 0.296
CC-IMTmax 1.184 (0.368) 1.197 (0.400) 1.222 (0.456) 0.705
IMTmax 2.051 (0.812) 2.026 (0.803) 2.040 (0.849) 0.502
IMTmeanmax 1.258 (0.295) 1.252 (0.298) 1.247 (0.306) 0.300
Diameter 7.847 (0.854) 7.834 (0.862) 7.796 (0.839) 0.441
Progression
CC-IMTmean 0.009 (0.029) 0.009 (0.027) 0.006 (0.026) 0.193
IMTmean 0.019 (0.032) 0.019 (0.032) 0.017 (0.033) 0.508
CC-IMTmax 0.016 (0.096) 0.017 (0.093) 0.007 (0.098) 0.281
IMTmax 0.049 (0.164) 0.042 (0.156) 0.035 (0.178) 0.209
IMTmeanmax 0.026 (0.053) 0.026 (0.051) 0.023 (0.054) 0.240
IMTfastest 0.176 (0.149) 0.166 (0.139) 0.156 (0.147) 0.002
Diameter 0.003 (0.030) 0.005 (0.033) 0.003 (0.029) 0.749
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in both psychiatric and CMD. Whilst this study does not bring us any closer to understanding the mechanisms 
underlying the common pathological mechanisms, it does suggest that exploration of the SCZ-CMD loci could 
have clinical utility, irrespective of mechanistic understanding.
One limitation is that these analyses were conducted in individuals of European ancestry and as SNPs were 
filtered by MAF and linkage disequilibrium, it is not possible to generalise them to other populations. Indeed, to 
apply current information from European ancestry individuals to additional ancestry groups has the potential 
to be misleading and is certainly incomplete. Whilst there is a recognised  need11 and growing efforts around the 
world to explore genetics of disease in non-European ancestry individuals, it will take time to gain full insight 
into the genetic architecture of diseases in these ancestry groups.
Figure 3.  Sensitivity testing in UKB1. For comparison, IMPROVE MDS analysis using (a) MAF > 1% and 
(b) MAF > 10%. MDS analysis in UKB1 using (c) the same post-filtering SNPs as for IMPROVE, (d) the same 
pre-filtering SNPs with MAF > 1% in UKB1 and (e) the same pre-filtering SNPs with MAF > 10% in UKB1. Each 
data point is an individual therefore the individuals who are closer together are more genetically similar.
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Figure 4.  Comparison of the three clusters identified in (a) UKB1 and (b) UKB2 (lower panel). Each data point 
is an individual therefore the individuals who are closer together are more genetically similar.
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Another limitation is that the CardioMetabo and Immuno chips do not include all loci implicated in cardio-
metabolic disorders. Since these chips were described (2012 and 2011 respectively), many more loci involved in 
many more processes have been identified. However, as more and more samples are available for GWAS analyses, 
loci are being identified with smaller and smaller effect sizes. Therefore whilst not all possible information is 
captured by using the CardioMetabo and Immuno chips, the loci with the largest effects are represented.
Table 3.  Demographic characteristics of the UKB1 and UKB2 participants, by cluster. Highlighted in bold 
are the significant (p < 0.05) differences between groups. Where: *, adjusted to provide estimates of treatment-
naïve levels; na, not available; Statistical analyses compared levels or frequencies across groups 1, 2 and 3. 
Ungrouped (.) were omitted from the analyses). **P for Pearson’s chi square for categorical variables and 
Kruskal–Wallis for continuous variables.
UKB1 (N = 2,202) UKB2 (N = 20,181)
Group 1 2 3 P** 1 2 3 P**
N 443 (20.1) 1054 (47.9) 622 (28.2) 83 (3.8) 5972 (29.6) 9926 (45.7) 3558 (17.6) 1425 (7.1)
Male (%) 205 (46.3) 499 (47.3) 300 (48.2) 38 (45.8) 0.788 2837 (47.5) 4459 (48.3) 1745 (49.0) 718 (50.4) 0.323
Baseline
Age (years) 55.6 (7.7) 56.0 (7.4) 55.4 (7.7) 54.6 (7.9) 0.121 55.1 (7.4) 55.1 (7.5) 55.4 (7.5) 55.2 (7.5) 0.172
Weight (kg) 76.0 (14.2) 75.7 (14.2) 76.6 (15.2) 76.9 (14.9) 0.805 76.7 (15.0) 77.0 (14.7) 77.0 (14.6) 77.6 (15) 0.352
Waist (cm) 87 (13) 87 (12) 88 (13) 88 (12) 0.883 88 (13) 88 (13) 88 (13) 89 (13) 0.418
Hip (cm) 102 (8) 101 (8) 102 (8) 102 (8) 0.581 102 (8) 102 (8) 102 (8) 102 (8) 0.681
WHR 0.86 (0.09) 0.86 (0.09) 0.86 (0.09) 0.86 (0.09) 0.974 0.86 (0.09) 0.86 (0.09) 0.86 (0.09) 0.86 (0.09) 0.271
BMI (kg/m2) 26.5 (3.9) 26.3 (3.9) 26.4 (4.0) 26.4 (3.7) 0.492 26.6 (4.4) 26.6 (4.2) 26.6 (4.1) 26.8 (4.2) 0.506
SBP (mmHg) 135 (17) 136 (18) 135 (18) 133 (17) 0.822 135 (17) 136 (18) 136 (18) 136 (18) 0.002
DBP (mmHg) 81 (10) 81 (10) 81 (10) 80 (11) 0.822 81 (10) 82 (10) 82 (10) 82 (10) 0.060
SBP* (mmHg) 138 (20) 138 (19) 138 (20) 134 (17) 0.774 137 (19) 138 (20) 138 (19) 138 (20) 0.016
DBP* (mmHg) 83 (11) 83 (11) 83 (11) 81 (11) 0.550 83 (11) 83 (11) 83 (11) 83 (11) 0.164
T2D 14 (3.2) 18 (1.7) 13 (2.1) 1 (1.2) 0.208 154 (2.6) 192 (2.1) 67 (1.9) 32 (2.3) 0.044
HTN 197 (44.9) 457 (44.2) 285 (46.3) 35 (44.3) 0.931 2491 (43.6) 4097 (46.3) 1534 (44.6) 643 (46.6) 0.005
HTN medication 75 (17.1) 158 (15.1) 91 (14.7) 8 (9.8) 0.395 817 (13.7) 1273 (13.9) 515 (14.5) 215 (15.2) 0.530
Lipid-lowering medication 43 (23.5) 80 (17.8) 45 (17.0) 4 (11.1) 0.174 509 (19.7) 741 (18.3) 292 (18.4) 135 (20.1) 0.344
ISH 4 (0.9) 10 (1.0) 6 (1.0) 1 (1.2) 0.361 81 (1.4) 118 (1.3) 47 (1.3) 13 (0.9) 0.920
Current smoking 29 (10.1) 63 (9.3) 45 (9.3) 7 (8.4) 0.900 375 (9.4) 586 (9.5) 193 (8.03) 80 (5.6) 0.092
Former smoking 185 (41.9) 436 (41.4) 252 (36.4) 32 (38.6) 0.072 2341 (39.3) 3622 (39.3) 1340 (37.8) 587 (41.2) 0.221
Follow-up
Age (years) 61.7 (7.6) 62.0 (7.3) 61.5 (7.6) 60.9 (7.6) 0.069 61.2 (7.4) 63.2 (7.5) 63.4 (7.5) 63.2 (7.5) 0.190
Weight (kg) 75.8 (14.3) 75.3 (14.3) 75.8 (15.4) 77.4 (14.5) 0.770 76.1 (15.2) 76.4 (14.9) 76.3 (14.8) 76.9 (15.1) 0.225
Waist (cm) 86 (12) 86 (12) 86 (12) 88 (11) 0.943 88 (13) 88 (12) 88 (12) 89 (12) 0.474
Hip (cm) 101 (8) 100 (8) 100 (8) 101 (8) 0.402 101 (9) 101 (9) 101 (8) 101 (9) 0.620
WHR 0.85 (0.08) 0.86 (0.08) 0.86 (0.08) 0.87 (0.08) 0.768 0.87 (0.09) 0.87 (0.09) 0.87 (0.09) 0.87 (0.08) 0.797
BMI (kg/m2) 26.6 (4.0) 26.3 (4.0) 26.3 (4.0) 26.8 (3.7) 0.457 26.5 (4.5) 26.6 (4.4) 26.5 (4.2) 26.7 (4.3) 0.511
SBP (mmHg) 137 (17) 138 (18) 137 (18) 134 (16) 0.332 137 (18) 138 (18) 137 (18) 137 (18) 0.385
DBP (mmHg) 79 (10) 79 (10) 78 (10) 78 (9) 0.381 78 (10) 79 (19) 78 (10) 78 (10) 0.171
SBP* (mmHg) 140 (20) 141 (20) 140 (21) 136 (17) 0.428 141 (20) 141 (20) 141 (20) 141 (20) 0.466
DBP* (mmHg) 81 (11) 81 (11) 81 (12) 80 (10) 0.370 81 (11) 81 (11) 81 (11) 81 (11) 0.316
T2D 22 (5.0) 32 (3.0) 23 (3.7) 2 (2.4) 0.186 267 (4.5) 387 (4.2) 149 (4.2) 64 (4.5) 0.682
HTN 225 (51.6) 556 (53.3) 304 (49.4) 36 (43.4) 0.127 3647 (61.6) 5727 (62.6) 2151 (61.0) 889 (62.8) 0.192
HTN medication 95 (21.5) 222 (21.2) 136 (21.9) 13 (15.7) 0.978 1328 (22.3) 2111 (23.0) 805 (22.7) 324 (22.9) 0.649
Lipid-lowering medication 94 (25.2) 192 (21.9) 107 (20.9) 15 (21.2) 0.341 1374 (26.8) 2056 (26.0) 795 (26.1) 332 (27.2) 0.608
ISH 7 (1.6) 24 (2.3) 8 (1.3) 4 (4.9) 0.491 112 (1.9) 152 (1.7) 53 (1.5) 16 (1.1) 0.334
IMTmean (mm) 0.673 (0.114) 0.674 (0.118) 0.670 (0.122) 0.663 (0.140) 0.475 0.680 (0.123) 0.682 (0.126) 0.686 (0.127) 0.686 (0.127) 0.205
IMTmax (mm) 0.884 (0.172) 0.891 (0.183) 0.886 (0.182) 0.880 (0.217) 0.817 0.911 (0.201) 0.914 (0.208) 0.921 (0.212) 0.916 (0.204) 0.242
Current smoking 17 (6.1) 45 (6.7) 40 (8.2) 2 (2.4) 0.456 221 (5.6) 326 (5.4) 108 (4.6) 53 (3.7) 0.183
Former smoking 177 (40.5) 412 (39.7) 247 (35.8) 26 (31.3) 0.179 2231 (37.7) 3439 (37.6) 1279 (36.4) 559 (39.2) 0.346
MHQ
Nmax (% of group) 319 (72.0) 739 (70.1) 462 (74.3) 62 (74.7) 0.289 4285 (71.7) 6636 (66.9) 2549 (71.6) 1008 (70.7) 0.803
bd 3 (0.9) 17 (2.3) 5 (1.1) 3 (4.8) 0.108 55 (1.3) 93 (1.4) 31 (1.2) 17 (1.7) 0.748
mdd 89 (32.4) 178 (28.3) 133 (32.5) 10 (17.9) 0.357 1110 (30.7) 1593 (28.0) 572 (26.6) 237 (28.2) 0.002
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Figure 5.  Comparison of the three clusters identified in UKB2 in individuals (a) without and (b) with mental 
illness. Each data point is an individual therefore the individuals who are closer together are more genetically 
similar.
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In conclusion, this study provides proof of concept that common biology underlying mental and physical 
illness is probable and can distinguish subsets of individuals with differing metabolic profiles, even if full under-
standing of mechanisms is lacking. Given that large-scale genotyping is not available to healthcare providers and 
the differences between groups are subtle, there is currently limited potential for translation of this into clinical 
practice. Further investigation with longitudinal datasets, particularly in high CVD risk populations, would 
define whether or not there is potential for clinical value in this method.
Methods
Cohorts: phenotyping and genotyping. The IMPROVE study has been described  previously12,13. In 
short, 3700 individuals aged between 54–79 years with high CVD risk profiles (the presence of at least 3 clas-
sical CVD risk factors, including family history of CVD, type 2 diabetes, hypertension, hyperlipidaemia and 
smoking) were recruited from seven centres in Finland, Sweden, the Netherlands, France and Italy. At base-
line, individuals completed lifestyle and medical questionnaires and anthropometric measures taken. Blood was 
sampled for DNA extraction and clinical biochemistry and stored for further biochemical analyses. Detailed 
ultra-sound examination of the carotid intima-media thickness (cIMT) was conducted at baseline, 15 months 
and 30 months. Linear regression using all data points was used to calculate progression of cIMT. Mental illness 
was not assessed; however it is believed that if there is mental illness in this cohort it is likely to be subclinical. 
All participants provided written informed consent and the study was conducted in accordance with the Hel-
sinki Declaration. Ethical approval was granted by the Regional Ethics Review Boards at Karolinska Institutet, 
Stockholm Sweden, the Groupe Hôpitalier Pitie-Salpetriere, Paris, France, the Comitato Etico delle Aziende 
Sanitarie della regione Umbria, Perugia, Italy, the Ospedale Niguarda Ca´Granda, Milano, Italy, the University 
Hospital Groningen, Groningen, the Netherlands, the Hospital District of Northern Savo, Kuopio, Finland and 
the University of Eastern Finland, Kuopio, Finland.
The IMPROVE study was genotyped on the Illumina Cardio-Metabo14 and Immuno  chips15, therefore car-
diometabolic disorders (including immune and inflammatory components) were well represented. Standard 
quality control procedures were conducted, namely exclusion of SNPs for low call rate (< 95%) and deviation from 
Hardy–Weinberg Equilibrium (p < 1 × 10–6) and exclusion of samples for low call rate (< 95%), sex-mismatch, 
cryptic relatedness. Quality control was conducted on each chip separately, followed by a further round of qual-
ity control on the combined chip.
The UK Biobank (UKB) has been described  previously16,17. Approximately 500,000 volunteers aged 
39–73 years were recruited from 22 centres across the UK. At baseline, detailed questionnaires on sociodemo-
graphic factors, lifestyle factors and medical history were completed by all individuals. Measurements of anthro-
pometric variables were recorded and blood samples were taken for DNA extraction. Subsequently (4–8 years 
after baseline), subsets of participants were invited for follow-up measurements and extensive imaging. All 
participants provided written informed consent and ethical approval was granted by the NHS national Research 
Ethics Service. This work was conducted under projects #6533 (Smith) and #1755 (Pell).
Ultrasound measurement of cIMT was conducted in a pilot phase of ~ 2500 individuals (henceforth denoted 
as UKB1) followed by a subsequent phase including ~ 22,000 individuals (denoted UKB2) using the same recruit-
ment and measurement protocol. cIMT measurements were generally consistent with the measurements available 
in IMPROVE. A mental health/thoughts and feelings questionnaire was also completed by a subset of partici-
pants, which enabled estimation of life history of MDD and BD. For both UKB1 and UKB2, 73% of participants 
completed the mental health questionnaire.
Genome-wide genotyping was conducted and standard quality control procedures were applied by the UK 
Biobank  team18. Imputation was conducted using the Haplotype reference consortium and 1000 Genomes with 
standard pre- and post- imputation quality controls being applied by the UK Biobank team (further informa-
tion is provided  in18).
Multi‑dimensional scaling (MDS) to identify clusters. Genome-wide genetic loci reported to be asso-
ciated with  SCZ19,  MDD20 and  BD21 were identified. SNPs within these (SCZ, MDD or BD) loci which were 
present on the CardioMetabo and Immuno chips were  selected14,15 (denoted SCZ-CM SNPs, MDD-CM SNPs or 
BD-CM SNPs, respectively). SNPs with MAF > 1% were included (Supplementary Table 3). A schematic diagram 
of the analyses steps is provided in Fig. 1.
In IMPROVE, each set of SNPs (SCZ-CM SNPs, MDD-CM SNPs or BD-CM SNPs) were pruned by pairwise 
LD (parameters 50, 5, 0.1) using  PLINK22. Individuals with > 1% missing genetic data were excluded prior to 
clustering.
Clustering was performed using multi-dimensional scaling, implemented in PLINK, using default settings. 
Multidimensional scaling essentially measures similarity between individuals, in this case using the patterns 
of genetic variation as the assessment  criteria23,24. Individuals with similar genetic sequences are deemed more 
similar to each other than those with less similar genetic sequences. Clustering was also conducted using tSNE 
and PCA (Supplementary Methods).
Subsequently in UKB1, SCZ-cardiometabolic SNPs only were used and individuals with > 1% missing genetic 
data were excluded prior to clustering. MDS analyses was conducted using either exactly the same SNPs as were 
used in IMPROVE (ie SCZ-CM SNPs after filtering for MAF and LD in IMPROVE) or SCZ-CM SNPs with 
filtering for MAF and LD being done in UKB1.
Finally, in UKB2, Individuals with > 1% missing genetic data were excluded prior to clustering. MDS analysis 
was conducted on SCZ-CM SNPs with filtering for MAF and LD in UKB2, or on all SCZ SNPs after MAF filter-
ing and pruning in UKB2.
The first two MDS components (C1 and C2) were plotted for visual assessment.
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Choosing a negative control experiment is not straight forward, as current evidence suggests that most 
genetic variants are highly pleiotropic and that complex traits overlap with each other to a large degree. Despite 
some overlap with CMD or SCZ-related traits, SNPs in genetic loci associated with eye colour were used as a 
negative control experiment. The analysis was conducted in UKB2 with MAF > 10% filtering and pruning as 
described above.
Statistical analyses. In IMPROVE, Spearmans rank correlation coefficients were used to assess the rela-
tionship between the MDS components and latitude. For IMPROVE, UKB1 and UKB2, Differences between 
groups were assessed by Pearsons chi squared test for categorical values and Kruskal–Wallis test for continuous 
variables. All statistical analyses were conducted in Stata (version 11.0). The threshold for significance was set 
at p < 0.05. No adjustment for multiple testing was applied, because these analyses are exploratory rather than 
definitive and secondly because most of the cardiometabolic phenotypes tested are interrelated and thus are not 
independent tests.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author request.
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